Boehringer Ingelheim expands its business with Biosimilars

As part of its corporate strategy Boehringer Ingelheim is to establish a new separate business for the development and commercialisation of its own biosimilars.

Boehringer Ingelheim started more than 30 years ago as a pioneer in biopharmaceuticals with the development and manufacturing of biopharmaceutical therapeutics. Today Boehringer Ingelheim Biopharmaceuticals is one of the leading companies in this field straight following its strategy to serve best in class development and manufacturing for its clients and Boehringer Ingelheim itself.

“We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines”, commented Prof. Dr. Wolfram Carius, member of the Board of Managing Directors and responsible for Operations. “We feel confident that we are able to leverage our capabilities in product development, supply and clinical expertise at Boehringer Ingelheim to offer high quality Biosimilars understanding patients’ needs.”

For more information please visit http://www.boehringer-ingelheim.com